MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, ALGS had -$18,694K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$18,694K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of short-term investm...
    • Proceeds from issuance of common...
    • Stock-based compensation includi...
    • Others
Negative Cash Flow Breakdown
    • Purchase of short-term investmen...
    • Change in fair value of 2023 com...
    • Operating lease liabilities
    • Others

Cash Flow
2025-12-31
Net loss
-24,193
Accretion of discount on investments
2,188
Non cash lease expense
1,875
Change in fair value of 2023 common warrants
-60,184
Depreciation expense
930
Stock-based compensation including espp
5,044
Accounts payable
1,411
Accrued liabilities
-2,031
Operating lease liabilities
-3,112
Deferred revenue
-151
Other assets
-96
Net cash and cash equivalents used in operating activities
-82,503
Maturities of short-term investments
127,500
Purchase of short-term investments
164,889
Purchases of property and equipment
-437
Net cash and cash equivalents used in investing activities
-37,826
Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with pipe offering, net of costs
101,345
Payments on finance lease
14
Proceeds from the espp purchase
304
Net cash and cash equivalents provided by financing activities
101,635
Net decrease in cash, cash equivalents, and restricted cash
-18,694
Cash, cash equivalents, and restricted cash, beginning of period
37,107
Cash, cash equivalents, and restricted cash, end of period
18,413
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock, common...$101,345K Proceeds from the espppurchase$304K Net cash and cashequivalents provided by...$101,635K Canceled cashflow$14K Net decrease incash, cash...-$18,694K Canceled cashflow$101,635K Stock-based compensationincluding espp$5,044K Non cash leaseexpense$1,875K Accounts payable$1,411K Depreciation expense$930K Other assets-$96K Maturities of short-terminvestments$127,500K Payments on finance lease$14K Net cash and cashequivalents used in...-$82,503K Canceled cashflow$9,356K Net cash and cashequivalents used in...-$37,826K Canceled cashflow$127,500K Change in fair value of2023 common warrants-$60,184K Net loss-$24,193K Operating leaseliabilities-$3,112K Accretion of discount oninvestments$2,188K Accrued liabilities-$2,031K Deferred revenue-$151K Purchase of short-terminvestments$164,889K Purchases of property andequipment-$437K

Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics, Inc. (ALGS)